zanubrutinib

a Bruton tyrosine kinase (BTK) inhibitor for treatment of Waldenstrom macroglobulinemia

Also Known As:

(7S)-2-(4-phenoxyphenyl)-7-(1-(prop-2-enoyl)piperidin-4-yl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide; 7-(1-acryloyl-4-piperidinyl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo(1,5-a)pyrimidine-3-carboxamide; BGB-3111; Brukinsa

Networked: 162 relevant articles (17 outcomes, 52 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds

Experts

1.	Huang, Jane: 22 articles (01/2022 - 01/2018)
2.	Tam, Constantine S: 20 articles (01/2022 - 01/2018)
3.	Novotny, William: 14 articles (01/2022 - 09/2018)
4.	Opat, Stephen: 12 articles (01/2022 - 12/2019)
5.	Tedeschi, Alessandra: 10 articles (01/2022 - 09/2018)
6.	Trotman, Judith: 10 articles (01/2022 - 01/2018)
7.	Cohen, Aileen: 9 articles (01/2022 - 09/2018)
8.	Cull, Gavin: 8 articles (01/2022 - 12/2019)
9.	Guo, Haiyi: 7 articles (01/2022 - 01/2020)
10.	Xu, Wei: 7 articles (01/2022 - 10/2019)

Related Diseases

1.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/2022 - "Zanubrutinib Monotherapy for Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies." 09/01/2023 - "Zanubrutinib for the treatment of chronic lymphocytic leukemia." 08/01/2023 - "Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia." 07/01/2023 - "[New drug approval: Zanubrutinib in monotherapy for chronic lymphocytic leukemia]." 05/04/2023 - "Zanubrutinib in Chronic Lymphocytic Leukemia. "
2.	Neoplasms (Cancer) 01/01/2023 - "The selectivity of zanubrutinib and its superior efficacy, with a well-tolerated safety profile, have proven to be attractive options for other malignancies." 01/01/2023 - "In a preclinical study, zanubrutinib inhibited malignant B-cell proliferation and reduced tumor growth. " 01/01/2023 - "This study aims to evaluate anti-tumor activity and safety of zanubrutinib with R-CHOP (ZR-CHOP) in treatment naïve non-GCB DLBCL with extranodal involvement. " 08/01/2020 - "In addition to a confirmatory phase III trial, there are multiple ongoing studies evaluating zanubrutinib as part of two- and three-drug regimens in MCL and other B-cell malignancies. " 05/01/2020 - "These nonclinical study results suggest that zanubrutinib has a broad safety window and an optimal safety profile while treating patients with advanced cancers."
3.	Lymphoma (Lymphomas) 11/28/2023 - "Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study." 01/01/2021 - "A prospective phase 2 study evaluating the efficacy and safety of zanubrutinib in patients with vitreoretinal lymphoma is ongoing to validate our findings (ChiCTR2000037921)." 07/25/2023 - "Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphoma." 01/01/2023 - "Zanubrutinib in the Maintenance Treatment of Elderly People with Primary Central Nervous System Lymphoma: A Report of 2 Cases." 01/01/2021 - "The excellent BBB penetration of zanubrutinib supports its further investigation for the treatment of CNS lymphoma."
4.	Waldenstrom Macroglobulinemia (Macroglobulinemia) 02/01/2023 - "Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States." 12/08/2020 - "Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial." 01/01/2022 - "Zanubrutinib in Treating Waldenström Macroglobulinemia, the Last Shall Be the First." 01/01/2022 - "Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia." 01/01/2021 - "Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. "
5.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/01/2022 - "Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study." 10/14/2021 - "Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials." 09/01/2023 - "Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis." 01/01/2023 - "Zanubrutinib in Mantle Cell Lymphoma Management: A Comprehensive Review." 02/01/2022 - "Zanubrutinib for mantle cell lymphoma, Waldenström's macroglobulinaemia."

Related Drugs and Biologics

1.	ibrutinib
2.	Agammaglobulinaemia Tyrosine Kinase
3.	Rituximab (Mabthera)
4.	acalabrutinib
5.	orelabrutinib
6.	venetoclax
7.	tirabrutinib
8.	Bendamustine Hydrochloride
9.	obinutuzumab
10.	Lenalidomide (CC 5013)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Duration of Therapy
4.	Intravitreal Injections
5.	Hematopoietic Stem Cell Transplantation